RecruitingPhase 1NCT07483827

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

Studying C3 glomerulopathy

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: eleva GmbH
Principal Investigator: Bernd Jilma, Prof.
Medical University of Vienna
Intervention: CPV-104/Placebo(drug)
Enrollment: 39 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (16)

Medizinische Universität Wien, Vienna, Austria
Cliniques universitaires Saint-Luc, Brussels, Belgium
Fakultni Thomayerova nemocnice, Prague, Czechia
Hôpital Européen Georges-Pompidou HEGP, Paris, France
Centre Hospitalier Universitaire De Toulouse, Toulouse, France
Laiko General Hospital Of Athens, Athens, Greece
Pauls Stradins Clinical University Hospital, Riga, Latvia
Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
Amsterdam UMC Stichting, Amsterdam, Netherlands
Hospital Curry Cabral - Centro Hospitalar de Lisboa Central - ULS Sao José, Lisbon, Portugal
Fundacio Puigvert, Barcelona, Spain
Hospital Universitario 12 De Octubre, Madrid, Spain
Clinica Universidad De Navarra, Pamplona, Spain
Hospital Universitario Virgen De La Macarena, Seville, Spain
University Hospital Virgen Del Rocio S.L., Seville, Spain
+1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07483827 on ClinicalTrials.gov

Other trials for C3 glomerulopathy

Additional recruiting or active studies for the same condition.

See all trials for C3 glomerulopathy →

← Back to all trials